Adding the new molecularly targeted agent bortezomib to a standard chemotherapy regimen of gemcitabine and carboplatin prolongs survival in patients with advanced non-small cell lung cancer, according to results from a phase II trial led by UC Davis Cancer Center.
In the study, patients taking bortezomib plus gemcitabine and carboplatin had a median survival of 11 months, reported Angela Davies, an assistant professor of hematology and oncology at UC Davis Cancer Center and lead author of the study. In comparison, 9 months is the longest median survival seen in past SWOG trials of platinum-based chemotherapy treatments for advanced non-small cell lung cancer.
"These survival results are among the best ever reported in patients with NSCLC," Davies said. "We look forward to further study of bortezomib in combination with chemotherapy as treatment for NSCLC in a larger, phase III trial." In the study, 114 newly diagnosed stage IV and selected stage IIIB patients received gemcitabine and carboplatin in combination with bortezomib. The median overall survival was 11 months; one-year survival was 46 percent, with a median five-month progression-free survival. Other key findings:
- 66 percent of patients benefited from the therapy, experiencing tumor shrinkage or disease stabilization
- The treatment was well tolerated; the most common side effects were neutropenia, a very low white-blood cell count; thrombocytopenia, a very low platelet count; and fatigue.
The study was supported by grants from the National Cancer Institute.